EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial

Bhumsuk Keam iD, Min Hee Hong iD, Seong Hoon Shin iD, Seong Gu Heo iD, Ji Eun Kim iD, Hee Kyung Ahn, Yun-Gyoo Lee iD, Keon-Uk Park iD, Tak Yun, Keun-Wook Lee iD, Sung-Bae Kim iD, Sang-Cheol Lee iD und 10 weitere

Journal of Clinical Oncology · 10.02.2024 · 42 (5) · 507-517

DOI: 10.1200/jco.22.02786 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2024. Verfasst von Bhumsuk Keam und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Head and Neck Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A precise oncologic approach for head and neck squamous cell carcinoma (HNSCC) is necessary. We performed a genomic profile-based umbrella trial for the patients with platinum-refractory recurrent and/or metastatic HNSCC. METHODS In this multicenter, open-label, single-arm phase II trial, we performed targeted next-generation sequencing (NGS). Patients were assigned to each treatment arm on the basis of their matching genomic profiles: arm 1, alpelisib, a PIK3CA inhibitor; arm 2, poziotinib, an epidermal growth factor receptor/HER2 inhibitor; arm 3, nintedanib, an fibroblast growth factor receptor inhibitor; and arm 4, abemaciclib, a CDK4/6 inhibitor. If there was no matching target, patients were allocated to arm 5, duvalumab ± tremelimumab, anti–PD-L1/cytotoxic T-cell lymphocyte-4 inhibitor. When progressive disease (PD) occurred in arms 1-4, cross over to arm 5 was allowed. The primary end point was disease control rate (DCR) in arm 1 and overall response rate (ORR) in arms 2-5 by investigator assessment. RESULTS Between October 2017 and August 2020, 203 patients were enrolled, including crossover. In arm 1, the ORR was 21.2% and DCR was 65.6%. The ORR was 0% for arm 2, 42.9% for arm 3, 0% for arm 4, and 15.6% for arm 5. In the case of PD with durvalumab, tremelimumab was added, and the ORR for durvalumab + tremelimumab was 2.2%. The median progression-free survival was 3.4, 3.2, 5.6, 1.6, and 1.7 months for each arm, respectively. The median overall survival was 12.4, 6.1, 11.1, 9.1, and 12.7 months, respectively. Overall, the toxicity profiles were manageable, and there were no treatment-related deaths. CONCLUSION To our knowledge, this study is the first biomarker-driven umbrella trial for platinum-refractory HNSCC using matched molecular targeted agents. We found that NGS-based genomic phenotyping was methodologically feasible and applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsHead and Neck NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsBiomarkersNeoplasm Recurrence, LocalPlatinumSquamous Cell Carcinoma of Head and Neck

Substanzen

Antineoplastic AgentsBiomarkersPlatinum

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Divison of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea.
  • Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Division of Cancer Data Science, National Cancer Center, Goyang, Republic of Korea.

ORCID-Profile: Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Yun-Gyoo Lee, Keon-Uk Park, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Sang Hee Cho, So Yeon Oh, Shinwon Hwang, Sangwoo Kim, Hye Ryun Kim, Hwan Jung Yun

Zitieren

APA

Keam, B., Hong, M. H., Shin, S. H., Heo, S. G., Kim, J. E., Ahn, H. K., Lee, Y. G., Park, K. U., Yun, T., Lee, K. W., Kim, S. B., Lee, S. C., Kim, M. K., Cho, S. H., Oh, S. Y., Park, S. G., Hwang, S., Nam, B. H., Kim, S., …, & KCSG TRIUMPH Investigators (2024). Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial. Journal of Clinical Oncology, 42(5), 507-517. https://doi.org/10.1200/jco.22.02786

Vancouver

Keam B, Hong MH, Shin SH, Heo SG, Kim JE, Ahn HK, et al. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial. Journal of Clinical Oncology. 2024;42(5):507-517. doi:10.1200/jco.22.02786

BibTeX
@article{Keam2024,
  author = {Keam, Bhumsuk and Hong, Min Hee and Shin, Seong Hoon and Heo, Seong Gu and Kim, Ji Eun and Ahn, Hee Kyung and Lee, Yun-Gyoo and Park, Keon-Uk and Yun, Tak and Lee, Keun-Wook and Kim, Sung-Bae and Lee, Sang-Cheol and Kim, Min Kyoung and Cho, Sang Hee and Oh, So Yeon and Park, Sang-Gon and Hwang, Shinwon and Nam, Byung-Ho and Kim, Sangwoo and Kim, Hye Ryun and Yun, Hwan Jung and KCSG TRIUMPH Investigators, KCSG TRIUMPH Investigators},
  title = {Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {5},
  pages = {507--517},
  doi = {10.1200/jco.22.02786}
}
Kostenlos starten →